Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of R3R01 on Albuminuria in Diabetic Kidney Disease
NCT06600412Phase 2Recruiting
- Sponsor
- River 3 Renal Corp
- Start
- Oct 2024
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic kidney disease (DKD) comparing R3R01 with Placebo (2 arms). Primary endpoint: Urinary Albumin-to-Creatinine Ratio at 12 weeks. Started Oct 2024; status: recruiting.
02
Drugs
R3R01
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06600412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06600412.